For the year ending 2025-12-31, SABS had $1,604,714 increase in cash & cash equivalents over the period. -$45,708,267 in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | 13,273,683 |
| Depreciation and amortization | 2,994,763 |
| Amortization of finance right-of-use assets | 86,823 |
| Stock-based compensation expense | 5,210,647 |
| Net realized and unrealized gain on investment in short-term securities | 73,967 |
| Changes in fair value of warrant liabilities | -62,754,186 |
| Accretion of discounts on short-term investments | 88,631 |
| Write-off of deferred issuance costs | 261,105 |
| Accrued interest receivable | 891,826 |
| Prepaid expenses and other current assets | 5,285,259 |
| Operating lease right-of-use assets and liabilities, net | -67,420 |
| Accounts payable | 1,482,793 |
| Accrued expense and other current liabilities | 941,524 |
| Net cash used in operating activities | -44,775,111 |
| Proceeds from the sale of equipment | 500 |
| Purchases of equipment | 933,156 |
| Purchases of investment securities | 142,035,560 |
| Sales and maturities of investments | 21,262,086 |
| Net cash used in investing activities | -121,706,130 |
| Proceeds from the 2025 pipe, net of series b issuance costs | 168,729,827 |
| Payment of deferred issuance costs | 758 |
| Principal payments of notes payable | 275,849 |
| Principal payments on finance leases | 142,563 |
| Tax payments for share settlement of restricted stock units | 11,205 |
| Net cash provided by (used in) financing activities | 168,299,452 |
| Effect of exchange rate changes on cash and cash equivalents | -213,497 |
| Net increase (decrease) in cash and cash equivalents | 1,604,714 |
| Beginning of period | 8,897,966 |
| End of period | 10,502,680 |
SAB Biotherapeutics, Inc. (SABS)
SAB Biotherapeutics, Inc. (SABS)